查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585839

支气管炎治疗药物市场：按适应症、治疗方法、药物类别和最终用户 - 全球预测 2025-2030

Bronchitis Treatment Market by Indication (Acute Bronchitis, Chronic Bronchitis), Treatment (Drugs, Oxygen Therapy), Class of Drugs, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年支气管炎治疗药物市值为67.2亿美元，预计2024年将达71.6亿美元，复合年增长率为6.75%，预计到2030年将达到106.2亿美元。

支气管炎治疗药物市场涵盖广泛的医疗干预措施，旨在减轻支气管炎的症状并解决支气管炎的原因，其特征是肺部支气管发炎。这些治疗范围从抗生素和支气管扩张剂等药物到加湿器和肺部復健等非药物治疗。这种疾病的流行凸显了对有效支气管炎治疗的需求，而空气污染、吸烟和病毒感染等因素又加剧了这种疾病。这些治疗的应用范围从急性支气管炎到慢性支气管炎，最终用途主要在医院、诊所和居家照护。主要成长动力包括呼吸健康意识的提高、药物配方的进步以及医疗基础设施投资的增加。利用基因研究来开发个人化医疗方法，根据患者情况量身订做更有效的治疗方法是有潜在机会的。数位医疗技术提供了另一种成长途径，透过远端医疗解决方案改善治疗的可近性，特别是在农村地区。

主要市场统计
基准年[2023] 67.2亿美元
预测年份 [2024] 71.6亿美元
预测年份 [2030] 106.2亿美元
复合年增长率（%） 6.75%

儘管有这些机会，市场仍面临重大挑战，包括对长期使用某些药物的副作用和抗生素抗药性的担忧。监管障碍和研发成本也对新治疗方法的有效商业化构成障碍。新兴市场缺乏意识和获得医疗保健的机会不足，进一步限制了市场开拓。创新可能会在一些领域蓬勃发展，例如开发联合治疗以提高疗效并最大限度地减少副作用，以及在预测分析和患者管理中使用人工智慧来改善治疗结果。该市场的特点是竞争激烈，主要企业投资于研发，以实现产品差异化并赢得市场占有率。透过专注于永续性、加强患者教育以及促进製药公司、科技公司和公共卫生机构之间的合作，我们可以克服现有的市场限制并实现显着成长。

市场动态：揭示快速发展的支气管炎药物市场的关键市场洞察

供应和需求的动态交互作用正在改变支气管炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性阻塞性肺病（COPD）患者增加
    • 政府和私人组织增加医疗保健支出
    • 政府和医疗机构加强意识提升
  • 市场限制因素
    • 替代品的可用性和产品的高成本
  • 市场机会
    • 持续进行研究和开发活动，以改善支气管炎治疗的呼吸治疗方法
    • 支气管炎治疗中个人化医疗越来越偏好
  • 市场挑战
    • 严格且耗时的法规环境

波特五力：驾驭支气管炎药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对支气管炎治疗药物市场的影响

外部宏观环境因素在塑造支气管炎治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解支气管炎治疗药物市场的竞争状况

支气管炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵支气管炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估支气管炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘支气管炎治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对支气管炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性阻塞性肺病（COPD）患者盛行率上升
      • 政府和私人组织增加医疗保健支出
      • 政府和医疗机构加强提高人们对支气管炎的认识
    • 抑制因素
      • 替代品的可用性和产品的高成本
    • 机会
      • 持续研发活动以改善支气管炎治疗药物的呼吸治疗
      • 人们对治疗支气管炎的个人化药物越来越感兴趣
    • 任务
      • 耗时且严格的法规环境
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 支气管炎治疗药物市场（依适应症）

  • 急性支气管炎
  • 慢性支气管炎

第七章 依治疗分类的支气管炎治疗药物市场

  • 药品
  • 氧气疗法

第八章 依药物类型分類的支气管炎治疗药物市场

  • 发炎药
  • 抗生素
  • 支气管扩张剂

第九章支气管炎治疗药物市场：依最终使用者分类

  • 诊所
  • 医院药房
  • 零售药房

第十章 北美和南美支气管炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区支气管炎治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的支气管炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • American Well Corporation
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cigna Corporation
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc
  • Lupin Limited
  • Melinta Therapeutics, Inc.
  • Merck and Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • TelaCare Health Solutions, LLC
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-A26E0E574296

The Bronchitis Treatment Market was valued at USD 6.72 billion in 2023, expected to reach USD 7.16 billion in 2024, and is projected to grow at a CAGR of 6.75%, to USD 10.62 billion by 2030.

The bronchitis treatment market encompasses a range of medical interventions aimed at relieving symptoms and addressing the causes of bronchitis, a condition characterized by inflammation of the bronchi in the lungs. This market's scope spans pharmaceuticals, including antibiotics and bronchodilators, and non-pharmacological treatments like humidifiers and pulmonary rehabilitation. The necessity for effective bronchitis treatment is underscored by the condition's prevalence, which is exacerbated by factors such as air pollution, smoking, and viral infections. The application of these treatments varies from acute to chronic bronchitis, with primary end-use in hospitals, clinics, and for in-home care. Key growth drivers include increasing awareness about respiratory health, advancements in drug formulations, and rising investments in healthcare infrastructure. There is a potential opportunity in developing personalized medicine approaches, leveraging genetic research to tailor treatments more effectively to patient profiles. Digital health technology offers another growth avenue through telemedicine solutions, improving access to treatment, especially in rural areas.

KEY MARKET STATISTICS
Base Year [2023] USD 6.72 billion
Estimated Year [2024] USD 7.16 billion
Forecast Year [2030] USD 10.62 billion
CAGR (%) 6.75%

Despite these opportunities, the market faces significant challenges, including the side effects associated with long-term use of certain medications and antibiotic resistance concerns. Regulatory hurdles and the cost of research and development also pose barriers to the effective commercialization of new treatments. Market growth is further restrained by a lack of awareness and inadequate healthcare access in developing regions. Innovation can thrive in areas such as the development of combination therapies that enhance efficacy and minimize side effects, or in the utilization of AI for predictive analytics and patient management to improve treatment outcomes. The market is characterized by a competitive nature with key players investing in R&D to differentiate their offerings and capture market share. Maintaining a focus on sustainability, enhancing patient education, and fostering collaborations across pharmaceutical companies, technology firms, and public health organizations can contribute to overcoming existing market limitations and achieving substantial growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchitis Treatment Market

The Bronchitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic obstructive pulmonary disease (COPD) patients
    • Growing healthcare expenditure by governments and private organizations
    • Increasing initiatives by government and healthcare organizations to create awareness about bronchitis
  • Market Restraints
    • Availability of alternatives and high cost of products
  • Market Opportunities
    • Ongoing research and development activities for improving respiratory therapies for bronchitis treatment
    • Increasing preference for personalized medicines for bronchitis treatment
  • Market Challenges
    • Time consuming and stringent regulatory environment

Porter's Five Forces: A Strategic Tool for Navigating the Bronchitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchitis Treatment Market

A detailed market share analysis in the Bronchitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchitis Treatment Market

A strategic analysis of the Bronchitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchitis Treatment Market, highlighting leading vendors and their innovative profiles. These include American Well Corporation, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cigna Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson Services, Inc, Lupin Limited, Melinta Therapeutics, Inc., Merck and Co. Inc., Novartis International AG, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A, Sun Pharmaceutical Industries Ltd., TelaCare Health Solutions, LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Acute Bronchitis and Chronic Bronchitis.
  • Based on Treatment, market is studied across Drugs and Oxygen Therapy.
  • Based on Class of Drugs, market is studied across Anti-inflammatory Drugs, Antibiotics, and Bronchodilator.
  • Based on End User, market is studied across Clinics, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic obstructive pulmonary disease (COPD) patients
      • 5.1.1.2. Growing healthcare expenditure by governments and private organizations
      • 5.1.1.3. Increasing initiatives by government and healthcare organizations to create awareness about bronchitis
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternatives and high cost of products
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for improving respiratory therapies for bronchitis treatment
      • 5.1.3.2. Increasing preference for personalized medicines for bronchitis treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming and stringent regulatory environment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchitis Treatment Market, by Indication

  • 6.1. Introduction
  • 6.2. Acute Bronchitis
  • 6.3. Chronic Bronchitis

7. Bronchitis Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Drugs
  • 7.3. Oxygen Therapy

8. Bronchitis Treatment Market, by Class of Drugs

  • 8.1. Introduction
  • 8.2. Anti-inflammatory Drugs
  • 8.3. Antibiotics
  • 8.4. Bronchodilator

9. Bronchitis Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospital Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Bronchitis Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bronchitis Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bronchitis Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. American Well Corporation
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim International GmbH
  • 4. Cadila Pharmaceuticals Limited
  • 5. Cigna Corporation
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline Pharmaceuticals Limited
  • 10. Johnson & Johnson Services, Inc
  • 11. Lupin Limited
  • 12. Melinta Therapeutics, Inc.
  • 13. Merck and Co. Inc.
  • 14. Novartis International AG
  • 15. Pfizer Inc.
  • 16. Reckitt Benckiser Group PLC
  • 17. Sanofi S.A
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. TelaCare Health Solutions, LLC
  • 20. Teva Pharmaceutical Industries Ltd.
  • 21. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRONCHITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRONCHITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ACUTE BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY BRONCHODILATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. BRONCHITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BRONCHITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023